Anti-HER2 treatment in everyday practice: how we treat older women with breast cancer differently
Anti-HER2 therapy use declined substantially after the age of 75 even when accounting for comorbidities and polypharmacy. Chronological age appears important in planning treatment for patients with HER2 + BC. Specific guidelines pertaining to older patients with HER2 + BC are needed to avoid potential undertreatment.
Authors
- Sarah Hjorth (ORCID: https://orcid.org/0000-0003-2841-5868)
- Edoardo Botteri (ORCID: https://orcid.org/0000-0002-9023-8068)
- Giske Ursin (ORCID: https://orcid.org/0000-0002-0835-9507)
- K. F. Vandraas
- B. K. Andreassen
- C. B. Trewin-Nybråten
- N. C. Støer
Institutions
- University of Southern California (US)
- Oslo University Hospital (NO)
- Norwegian Institute of Public Health (NO)
- University of Oslo (NO)
- Cancer Registry of Norway (NO)
- Norwegian Womens Public Health Association (NO)
Publication Details
- Journal
- Breast Cancer Research and Treatment
- Published
- 2026-01-01
- DOI
- https://doi.org/10.1007/s10549-025-07888-z
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00